Washington University Cancer Genomics and Outcomes Research STRENGTH Program

华盛顿大学癌症基因组学和结果研究优势计划

基本信息

  • 批准号:
    9054096
  • 负责人:
  • 金额:
    $ 20.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-14 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Washington University Cancer Genomics and Outcomes Research STRENGTH (Short-Term Research Education and Growth Through Hands-On Experiences) Program Background: Advances in genomics and cancer biology have transformed the treatment of patients with cancer. The new generation of trainees needs to be educated in the emerging discipline of cancer genomics. Even as our understanding of cancer genomics continues at an extraordinary pace, the costs of health care in general and cancer care, in particular, have been increasing at a level that will soon be unsustainable. The proposed Washington University Cancer Genomics and Outcomes Research STRENGTH (Short-Term Research Education and Growth Through Hands-On Experiences) Program, from now on referred to as the STRENGTH program, is uniquely tailored to educate physicians-in-training on two key aspects that are critical for cancer research today: cancer genomics and outcomes research. Goals and Objectives: The overall goal for this research education program is to develop and implement a first of its kind at Washington University (WU) in St. Louis. The STRENGTH program is designed for postdoctoral scholars (PhDs and MDs) who are still under training and interested in pursuing patient oriented cancer research. The aims of this program are to: 1) develop and implement an innovative model internet- based educational program in genomics and outcomes research coupled with workshops and seminars 2) train 8-10 postdoctoral fellows and researchers annually over a five-year period in cancer genomics and outcomes research; 3) conduct ongoing mentoring that includes hands-on research training experiences, structured mentorship meetings and intensive career development activities; 4) evaluate all research education program components and track participants' career development over time; and 5) actively disseminate program components to encourage adoption by other individuals and institutions. Significance and Innovation: The existing cancer-related training programs target mainly undergraduate students or junior faculty physicians. There is an urgent need to develop short-term structured specialized programs targeting postdoctoral scholars still in-training (PhDs and MDs), interested in pursuing a career in patient-oriented cancer research. The STRENGTH program is highly innovative and has unique strengths: 1) It addresses the current gap in cancer genomics and outcomes research training opportunities for postdoctoral scholars in training (PhDs and MDs), referred to as postdoctoral scholars from now on; 2) It utilizes a hybrid learning model that includes web-based and face-to-face didactic training combined with hands-on research opportunities; 3) It places a strong emphasis on mentoring and career development; 4) It includes a multi- disciplinary faculty team with a proven track record in establishing successful training programs; and 5) It will be disseminated widely and can be applied to other disciplines and specialty training areas.
描述(由申请人提供):华盛顿大学癌症基因组学和成果研究实力(短期研究教育和通过实践经验的增长)计划背景:基因组学和癌症生物学的进步已经改变了癌症患者的治疗。新一代的受训者需要接受癌症基因组学这一新兴学科的教育。即使我们对癌症基因组学的理解继续以非凡的速度发展,但一般医疗保健,特别是癌症护理的成本一直在以很快就无法持续的水平增长。拟议的华盛顿大学癌症基因组学和成果研究实力(短期研究教育和通过实践经验的增长)计划,从现在起被称为实力计划,是专门为教育医生在培训对当今癌症研究至关重要的两个关键方面:癌症基因组学和成果研究。目的和目标:这项研究教育计划的总体目标是在圣路易斯的华盛顿大学(WU)开发和实施第一个同类项目。该实力计划是专为博士后学者(博士和医学博士)谁仍在接受培训,并有兴趣在追求病人为导向的癌症研究。该项目的目标是:1)开发和实施一个创新的基于互联网的基因组学和成果研究教育项目,并结合讲习班和研讨会2)在五年内每年培训8-10名博士后研究员和研究人员进行癌症基因组学和成果研究; 3)进行持续的指导,包括实践研究培训经验,结构化的导师会议和密集的职业发展活动; 4)评估所有研究教育计划的组成部分,并跟踪参与者的职业发展随着时间的推移;和5)积极传播计划的组成部分,以鼓励其他个人和机构采用。意义和创新:现有的癌症相关培训计划主要针对本科生或初级医师。迫切需要开发针对仍在培训中的博士后学者(博士和医学博士)的短期结构化专业课程,他们有兴趣从事以患者为导向的癌症研究。STRENGTH计划具有高度创新性,具有独特优势:1)它解决了目前癌症基因组学和成果研究的空白,为博士后学者提供培训机会(博士和医学博士),从现在起称为博士后学者; 2)它利用混合学习模式,包括基于网络和面对面的教学培训与实践研究机会相结合; 3)它非常强调辅导和职业发展; 4)它包括一个多学科的教师团队,在建立成功的培训计划方面有着良好的记录; 5)它将被广泛传播,并可应用于其他学科和专业培训领域。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ramaswamy Govindan其他文献

Ramaswamy Govindan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ramaswamy Govindan', 18)}}的其他基金

Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer
小细胞肺癌化疗耐药机制的基因组和功能鉴定
  • 批准号:
    10002189
  • 财政年份:
    2018
  • 资助金额:
    $ 20.04万
  • 项目类别:
Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer
小细胞肺癌化疗耐药机制的基因组和功能鉴定
  • 批准号:
    10241343
  • 财政年份:
    2018
  • 资助金额:
    $ 20.04万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9446706
  • 财政年份:
    2017
  • 资助金额:
    $ 20.04万
  • 项目类别:
Washington University Cancer Genomics and Outcomes Research STRENGTH Program
华盛顿大学癌症基因组学和结果研究优势计划
  • 批准号:
    9266376
  • 财政年份:
    2015
  • 资助金额:
    $ 20.04万
  • 项目类别:
GENOMIC HARBINGERS OF BRAIN METASTASIS IN NON SMALL CELL LUNG CANCER
非小细胞肺癌脑转移的基因组先兆
  • 批准号:
    9067330
  • 财政年份:
    2014
  • 资助金额:
    $ 20.04万
  • 项目类别:
GENOMIC HARBINGERS OF BRAIN METASTASIS IN NON SMALL CELL LUNG CANCER
非小细胞肺癌脑转移的基因组先兆
  • 批准号:
    8884567
  • 财政年份:
    2014
  • 资助金额:
    $ 20.04万
  • 项目类别:
GENOMIC HARBINGERS OF BRAIN METASTASIS IN NON SMALL CELL LUNG CANCER
非小细胞肺癌脑转移的基因组先兆
  • 批准号:
    9288141
  • 财政年份:
    2014
  • 资助金额:
    $ 20.04万
  • 项目类别:
GENOMIC HARBINGERS OF BRAIN METASTASIS IN NON SMALL CELL LUNG CANCER
非小细胞肺癌脑转移的基因组先兆
  • 批准号:
    9249709
  • 财政年份:
    2014
  • 资助金额:
    $ 20.04万
  • 项目类别:
QUANTITATIVE DETECTION OF CLINICALLY ACTIONABLE MUTATIONS IN LUNG CANCER
肺癌临床上可行的突变的定量检测
  • 批准号:
    8608503
  • 财政年份:
    2013
  • 资助金额:
    $ 20.04万
  • 项目类别:
QUANTITATIVE DETECTION OF CLINICALLY ACTIONABLE MUTATIONS IN LUNG CANCER
肺癌临床上可行的突变的定量检测
  • 批准号:
    8445631
  • 财政年份:
    2013
  • 资助金额:
    $ 20.04万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.04万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 20.04万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 20.04万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了